Previous 10 | Next 10 |
We are value investors. In constructing portfolios for our clients, we seek out companies that we believe are trading in the market at significant discounts to their underlying value. These businesses must offer significant profit potential and be run by managers who think and act as owne...
Grifols S.A. (NASDAQ:GRFS) traded at a new 52-week high today of $26.00. So far today approximately 71.7 million shares have been exchanged, as compared to an average 30-day volume of 1.1 million shares. Grifols S.A. has overhead space with shares priced $11.55, or 3.5% below the average...
Update 1:25pm: Updates shares, adds Grifols no comment. Grifols SA (NASDAQ:GRFS) advanced 13% on speculation that the pharmaceuticals and chemicals maker has seen some takeover interest. There's some speculation that some private equity firms are looking at Grifols (GRFS), acco...
Grifols SA (NASDAQ:GRFS) advanced 6% on speculation that the pharmaceuticals and chemicals maker has seen some takeover interest. There's some speculation that some private equity firms are looking at Grifols (GRFS), according to a Betaville "uncooked" alert. One PE firm is sai...
FBT is a passive biotechnology ETF, which doesn’t pay any dividend. Baring the past one year, FBT’s price return has outperformed the S&P 500. Effective portfolio rebalancing may determine its future growth. For further details see: FBT: A Long Term Hol...
Grifols (OTCPK:GIKLY) is collaborating with Endpoint Health to develop and commercialize an Antithrombin III (AT-III) therapy to treat Sepsis. Under the agreement, Grifols will contribute its expertise in plasma-protein therapies and be the exclusive supplier of AT-III, a plasma protein that ...
Adma Biologics (NASDAQ:ADMA) activist holder Caligan Partners is said to be supportive of the company's ongoing strategic review. Adma rose 1.5.%. The activist would support a sale of the company for at least $3/share, according to a Dealreporter item, which cited sources familiar. Poten...
Grifols currently trading at a 30% discount to European specialty pharma. Biotest AG Investment analysis. Biotest R&D not priced in. For further details see: Grifols: Short-Term Turbulence But Long-Term Upside
Investing in the biotech industry is an art, not a science. While the potential for gains from groundbreaking therapies exists, the majority fail. By utilizing statistics, careful selection, and net present value calculations, it is quite easy to find a basket that fulfills your p...
There could be a downside to the consensus revenue and margins of Grifols (GRFS -4.0%) (OTCPK:GIKLY) (OTCPK:GIFLF), JPMorgan analyst James D Gordon warned, issuing the firm’s earnings preview for the Spanish plasma maker on Monday. After the comments, Grifols (NASDAQ:GRFS) ADRs have re...
News, Short Squeeze, Breakout and More Instantly...
2024-06-12 02:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Grifols 2023 Annual Report on Form 20-F filed with the SEC PR Newswire BARCELONA, Spain , April 19, 2024 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived me...
2024-03-23 01:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...